Procter & Gamble Co. (PG) just turned in a fiscal first quarter that looked, by most measures, like a company getting its groove back. Organic sales grew 4%, comfortably ahead of the 2.2% consensus. Organic volume rose 2.4%. Adjusted earnings climbed 1% to $2 per share, beating the $1.89 TD Cowen had penciled in. U.S. sales growth improved to 3%, and the company held or gained market share among 70% of its largest U.S. customers.

So why is TD Cowen still sitting on the sidelines? Because the cost side of the ledger is getting ugly, and pricing power is getting thin.

On Friday, TD Cowen analyst Robert Moskow kept his Hold rating on Procter & Gamble and raised his price forecast to $166 from $150. He also bumped up his earnings and sales estimates, pointing to stronger U.S. market share trends and improving execution. But Moskow openly questioned whether the recovery can last as inflationary pressures intensify.

The Turnaround Is Real, at Least for Now

The retail tracking data backs up the improvement. P&G's U.S. retail sales rose 4.5% during the calendar third quarter, outpacing category growth of 3%. That's a meaningful swing from earlier this year, when weaker market share trends had investors worried the company's restructuring efforts were sputtering.

Moskow thinks faster execution and organizational changes could help P&G return to its long-term organic sales growth range of 3% to 5%. That's the bull case, and it's not crazy. The company is clearly doing something right.

Here Comes the Oil Problem

But improving demand doesn't pay the bills when input costs are climbing. P&G raised its fiscal 2027 forecast for after-tax commodity inflation to $1.4 billion from $1 billion. Management also warned that cost pressures could increase further if oil prices remain near $113 per barrel.

The margin damage is already visible. First-quarter gross margin fell 152 basis points, while operating margin declined 75 basis points. Management expects second-quarter gross margin to contract about 200 basis points as higher commodity costs flow through the business. Moskow expects those higher input costs to weigh on profitability, particularly during the fiscal second quarter.

Then there's the pricing problem. P&G's first-quarter pricing increased just 0.4%, a reflection of intense promotional competition in the U.S. market. TD Cowen believes those competitive conditions could make it difficult for the company to raise prices enough to offset inflation. In other words, P&G can't simply pass the costs along to shoppers who are already being wooed with discounts.

Estimates Up, Enthusiasm Tempered

Moskow raised his fiscal 2027 organic sales growth estimate by 70 basis points to 3%, above the 2.3% consensus. He also lifted his fiscal 2027 core earnings forecast to $7.03 per share from $6.91, representing about 2% annual growth.

The revised $166 price target reflects a valuation of roughly 23 times TD Cowen's estimated forward earnings of $7.28 per share. That's not a screaming bargain, and Moskow knows it. He said the company needs to demonstrate sustained improvement before earning a more bullish rating, citing several periods of encouraging performance over the past two years that failed to translate into lasting momentum.

He also warned that persistently elevated oil prices could weigh on earnings into fiscal 2028. That's the kind of overhang that keeps an analyst from upgrading a stock even when the recent numbers look good.

For now, TD Cowen sees evidence that P&G's turnaround is progressing, but remains unconvinced that stronger sales can fully overcome rising costs. Investors will get another opportunity to assess the company's recovery strategy at its investor day on Nov. 19.

PG Price Action: Procter & Gamble shares were down 2.61% at $161.27 at the time of publication on Friday, according to market data.